ERBB2 and aneurysmal bone cyst: Paclitaxel plus bevacizumab (PB) therapy increases the progression-free survival (PFS) and overall response rate (ORR) of patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)1–4.